Originally published In Press as doi:10.1074/jbc.M108084200 on February 22, 2002
J. Biol. Chem., Vol. 277, Issue 21, 18986-18993, May 24, 2002
Enhancement of Hyperthermia-induced Apoptosis by Local
Anesthetics on Human Histiocytic Lymphoma U937 Cells*
Yoko
Arai,
Takashi
Kondo
§,
Kiyoshi
Tanabe
,
Qing-Li
Zhao
,
Fu-Jun
Li
,
Ryohei
Ogawa
,
Min
Li, and
Minoru
Kasuya
From the Department of Public Health and
Radiological
Sciences, Faculty of Medicine, Toyama Medical and Pharmaceutical
University, 2630 Sugitani, Toyama 930-0194, Japan
Received for publication, August 22, 2001, and in revised form, January 10, 2002
 |
ABSTRACT |
The combined effects of hyperthermia
at 44 °C and local anesthetics on apoptosis in human histiocytic
lymphoma U937 cells were investigated. When the cells were exposed to
hyperthermia for l0 min marginal DNA fragmentation and nuclear
fragmentation were observed. In the presence of amide-type local
anesthetics further enhancement was found depending on concentration.
The order of the concentration required for maximum induction was the
reverse order of the lipophilicity (prilocaine > lidocaine > bupivacaine). Western blotting revealed that in hyperthermia there
was initial release of Ca2+ from the intracellular
store site as indicated by increased expression of the type 1 inositol-1,4,5-trisphosphate receptor. However, the combination with
lidocaine did not induce any further enhancement. Lidocaine enhanced
the decrease in ATP content and the increase in intracellular
Ca2+ concentration in individual cells induced by
hyperthermia. In addition, superoxide formation, decrease in the
mitochondrial membrane potential, and activation of intracellular
caspase-3 were found in the cells treated with hyperthermia and
lidocaine. All of these were suppressed in part in the presence of the
intracellular Ca2+ ion chelator BAPTA-AM
(bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl). The present results indicate that local
anesthetics at optimal concentrations enhance hyperthermia-induced
apoptosis via Ca2+- and mitochondria-dependent
pathways. Initial release of Ca2+ from intracellular
store sites caused by hyperthermia and followed by the subsequent
increase in the intracellular Ca2+ concentration and the
additional activation of the mitochondrial caspase-dependent pathway (partly regulated by
intracellular Ca2+ concentration) plays a crucial role in
the enhancement of apoptosis induced by the combination of hyperthermia
and lidocaine.
 |
INTRODUCTION |
The effectiveness of hyperthermia combined with radiotherapy
in the treatment of various solid tumors has been demonstrated (1).
Furthermore, recent clinical randomized trials of patients with brain
tumors, recurrent or metastatic malignant melanoma, advanced breast
carcinoma, locally advanced pelvic tumors, and malignant germ cell
tumors clearly have indicated the advantages for patients treated with
hyperthermia combined with radiotherapy (2-6) or chemotherapy (7)
compared with radiotherapy alone. However, the uniform and precise
delivery of heat to tumors still remains a challenge. In many
circumstances the tumor cell killing is insufficient. Drugs that have
been discussed as overcoming this difficulty are heat sensitizers. An
ideal sensitizer would be nontoxic at normothermia but could become
cytotoxic at hyperthermic temperatures.
Local anesthetics belong to a class of clinically useful compounds that
exert a pharmacological effect by blocking nerve impulse propagation.
The involvement of cell membranes as the site for these drug actions
has been widely accepted, and many reports showing modification of cell
killing due to hyperthermia by
LAs1 have been published
(e.g. potentiation by procaine in murine L5178Y lymphoma
cells (8) and by lidocaine in murine FM3A mammary carcinoma cells (9),
potentiation of survival of tumor-bearing mice after hyperthermia
combined with lidocaine (10), enhancement of hyperthermia-induced tumor
regression by lidocaine in murine tumor models (11, 12), and
enhancement of cytotoxic effects of hyperthermia by dibucaine,
tetracaine, and procaine in hepatoma tissue culture cells (13)).
However, little is known about the modification and mechanism of
apoptosis when hyperthermia is combined with LAs.
Here we will present our recent findings that subtoxic levels of LAs
enhanced hyperthermia-induced apoptosis via the Ca2+- and
mitochondria-dependent pathways in human lymphoma U937
cells. Evidence for the cardinal roles of initial release of
Ca2+ from intracellular store sites due to hyperthermia and
the subsequent increase of [Ca2+]i and the
additional activation of the mitochondrial caspase-dependent pathway in enhancement of apoptosis
induced by the combination of hyperthermia and lidocaine will also be presented. In addition the potential usefulness of LAs as sensitizers of heat-induced apoptosis in cancer therapy will be discussed.
 |
EXPERIMENTAL PROCEDURES |
Cells and Hyperthermic Treatment--
The human histiocytic
lymphoma cell line (U937) was obtained from the Japanese Cancer
Research Resource Bank. Cells were grown in RPMI 1640 culture medium
supplemented with 10% heat-inactivated fetal bovine serum
(Invitrogen) at 37 °C in humidified air with 5%
CO2. The cells in log phase (doubling time is 23.5 h)
were used for the experiments after confirmation that they were free from any mycoplasma contamination.
We added LAs 5 min before heating, and hyperthermic treatments were
performed by the immersion of plastic culture tubes containing the cell
suspensions (3 ml) in a water bath (NTT-1200, Eyela, Tokyo, Japan) at
44.0 °C (± 0.05 °C). The temperature of the culture medium was
monitored with a digital thermometer (#7563, YOKOGAWA, Tokyo, Japan)
coupled with a 0.8-mm thermocouple.
Determination of DNA Fragmentation--
The amount of DNA
extracted from cells that had undergone DNA fragmentation was assayed
using the method of Sellins and Cohen (14) with a few modifications
(15). Briefly, the cells were lysed in a lysis buffer (10 mM Tris, 1 mM EDTA, 0.2% Triton X-100, pH 7.5)
and centrifuged at 13,000 × g for 10 min.
Subsequently, each DNA sample in the supernatant and the pellet was
precipitated in 12.5% trichloroacetic acid at 4 °C and quantified
using a diphenylamine reagent after hydrolysis in 5% trichloroacetic
acid at 90 °C for 20 min. The percentage of fragmented DNA in each
sample was calculated as the amount of DNA in the supernatant divided
by the total DNA for that sample (supernatant plus pellet).
Significance was assessed by a two-way analysis of variance followed by
a Fisher's PLSD test and was assumed for p values
<0.05.
Observation of DNA Ladder Formation--
DNA was extracted from
the treated cells using a Sepa Gene DNA extraction kit (Sanko Junyaku
Co. Ltd., Tokyo, Japan) and digested with RNase A (50 µg/ml, Sigma)
in TE buffer (10 mM Tris, 1 mM EDTA). The
purified DNA (1-3 µg/lane) was electrophoresed for 60 min at 100 V
in a 0.8% neutral agarose gel, and DNA-laddering was visualized by
staining with 0.5 µg/ml ethidium bromide and UVB illumination (16,
17).
Morphological Observation--
To identify the apoptotic cells
after exposure to hyperthermia, the cells harvested after 6 h of
incubation at 37 °C were washed with Dulbecco's PBS and collected
by centrifugation. The cells were fixed with methanol and acetic acid
(3:1) and spread on glass slides. After drying staining was performed
with 3% Giemsa solution (pH 6.8) for 15 min. The apoptotic cells were
determined by counting a total of 1,000 cells per sample in randomly
selected areas.
Flow Cytometry--
Because annexin V is a human protein with a
molecular mass of 36 kDa and a high affinity for
phosphatidylserine on the cell membrane, a FITC-labeled annexin V
kit (Immunotech, Marseilles, France) was used to detect
phosphatidylserine expression on the cell membrane as an end point of
early apoptosis (18). The samples were washed in cooled PBS at 4 °C
and centrifuged at 500 × g for 5 min. The resulting
pellets were adjusted to 106 cells/ml with the binding
buffer from a FITC-labeled annexin V kit. FITC-labeled annexin V (5 µl) and PI (5 µl) were added to the suspension (490 µl) and mixed
gently. After incubation for 10 min in the dark the cells were analyzed
with a flow cytometer (Epics XL, Beckman-Coulter, Miami, FL).
Determination of Intracellular Concentration of Calcium Ion in
Single Cells--
The cells were collected by centrifugation and
washed with HR (NaCl, 118 mM; KCl, 4.7 mM;
CaCl2, 2.5 mM; MgCl2, 1.13 mM; Na2HPO4, 1.0 mM;
glucose, 5.5 mM, and HEPES, 10 mM). The buffer
was supplemented with 0.2% bovine serum albumin (Sigma), minimal
Eagle's essential amino acids (Flow Laboratories, Irvine, UK), and 2 mM L-glutamine. Approximately 3 × 105 cells in 3 ml of HR were loaded with 5 mM
Fura-2/AM (Dojindo Lab., Kumamoto, Japan) for 30 min at 25 °C. The
cells loaded with Fura-2/AM were washed once with HR and twice with the
growth medium. Following centrifugation the cells were transferred to a
tube containing the culture medium with or without lidocaine (Sigma). After hyperthermia the cells were washed with HR, and an aliquot of
cell suspensions (10 ml) was transferred onto a glass-bottomed dish
coated with Cell-Tak (Genome Therapeutics). After addition of HR to the
dish, digital imaging of Fura-2 fluorescence was carried out using an
inverted microscope and a digital image processor (Argus 50/Ca,
Hamamatsu Photonics, Hamamatsu, Japan) as reported previously (19-21).
The fluorescence ratio (340 nm/380 nm) at 510 nm of emission wavelength
was converted to [Ca2+]i using the equation of
Grynkiewicz et al. (22). Significance was assessed by
Mann-Whitney test and was assumed for p values <0.05.
Assessment of MMP--
DiOC6(3) was employed for examining MMP.
After treatment with hyperthermia combined with or without lidocaine
cells were washed twice with PBS and were exposed to 40 nM
DiOC6(3) (Wako Pure Chemical, Tokyo, Japan) in 1 ml PBSF (PBS plus 1%
fetal bovine serum) for 15 min at 37 °C. The fraction of cells
showing low MMP was measured by flow cytometry.
Western Blot Analyses of Proteins--
The cells were lysed at a
density of 106 cells per 20 µl of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40
(v/v), 1% sodium deoxycholate, 0.05% SDS, 1 mM
phenylmethyl sulfonyl fluoride) for 20 min. After brief sonication the
lysates were centrifuged, and protein content in the supernatant was
measured using a Bio-Rad protein system. Western blot analyses of IP3R (1, 3) and
-actin were performed using specific polyclonal or
monoclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
Measurement of Intracellular Superoxide Anion
Radicals--
Superoxide anion levels were measured using the method
employed by Gorman et al. (23). We used the dye,
hydroethidine (Molecular Probes, Eugene, OR) which is oxidized by
superoxide anion radicals within the cell, which fluoresces when it
intercalates into DNA. Briefly, the cells (106 cells/ml)
were incubated with 2 µM hydroethidine for 15 min at 37 °C. After a second washing levels of the intracellular superoxide anion radicals were assessed using flow cytometry.
Single Cell Analysis of Intracellular Caspase
Activity--
The cell-permeable fluorogenic substrate
(PhiPhiLux-G1D2) was used to monitor the intracellular caspase-3
activity according to the manufacturer's recommendations (OncoImmunin,
Inc., Gaithersburg, MD). Briefly, the sample (106 cells/ml)
was gently centrifuged, and the cell pellet was resuspended with 50 µl of 10 µM PhiPhiLux-G1D2 substrate solution in RPMI 1640 supplemented with 10% fetal bovine serum. After incubation for
1 h at 37 °C in the dark the samples were washed once and diluted with 0.5 ml of ice-cold flow cytometry dilution buffer. The
fraction of cells showing high caspase-3 activities was measured by
flow cytometry (24).
Measurement of Intracellular ATP Level--
Intracellular ATP
level was measured using a CheckLite plus 250 kit (Kikkoman, Tokyo,
Japan). After treatment the cells were centrifuged at 1,000 rpm for 2 min, and the filtrate was removed. A cell suspension (2 × 105 cells/200 µl) was added to the lysis buffer (200 µl) and was kept for 5 min at 25 °C. Afterward the absorbency of
ATP, which was included in 100 µl of the cell suspension, was
measured by the administration of 100 µl of the emission reagent. The
intracellular ATP concentration was calculated from the standard curve
(from 2 × 10
7 M to 2 × 10
10 M concentration of ATP). Significance
was assessed by a two-way analysis of variance followed by a Fisher's
PLSD test and was assumed for p values <0.05.
 |
RESULTS |
Effects of LAs on Hyperthermia-induced Apoptosis--
To study the
ability of LAs to potentiate hyperthermia-induced apoptosis, DNA
fragmentation was examined when U937 cells were treated with
hyperthermia combined with three kinds of amide-type LAs (lidocaine,
bupivacaine, or prilocaine), which have different lipophilicities. Fig.
1 shows the effects of graded
concentrations of LAs on the DNA fragmentation when the cells were
incubated for 6 h at 37 °C after treatment with or without
hyperthermia at 44 °C for 10 min. The apparent enhancement of
hyperthermia-induced DNA fragmentation by LAs was observed at
concentrations of more than 0.5 mM. The order of
concentration of LAs for the maximum DNA fragmentation was
prilocaine > lidocaine > bupivacaine, and this was the
reverse order of lipophilicity and potency as anesthetic agents (25).
When the cells were treated with LAs at 37 °C no DNA fragmentation
induced by prilocaine was observed. In contrast, lidocaine and
bupivacaine increased DNA fragmentation at concentrations more than 2 and 1.5 mM, respectively. In addition, the DNA
fragmentation induced by bupivacaine decreased at a concentration of
1.5 mM. Because lidocaine is more effective with less
toxicity among the LAs in this study, it was used for the following
experiments.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 1.
Enhancement of DNA fragmentation by LAs in
U937 cells. U937 cells were treated with hyperthermia (44 °C,
10 min) in the presence or absence of LAs (lidocaine,
bupivacaine, and prilocaine) at different
concentrations. DNA fragmentation assay was carried out after a 6-h
incubation at 37 °C according to the method of Sellins and Cohen
(12). Data are presented as mean ± S.D. (n = 5).
|
|
The enhancement of DNA ladder formation after treatment with
hyperthermia and lidocaine was observed (Fig.
2). When the samples of cells stained
with Giemsa were examined under a light microscope a marked enhancement
of apoptotic change in the nuclei, especially nuclear fragmentation,
was observed in the samples treated with hyperthermia and lidocaine,
although hyperthermia alone induced marginal changes (Fig.
3, A-D). The percentage of
cells containing fragmented nuclei after the combined treatments was
3× higher than those of the samples treated with hyperthermia (Fig.
3E). These results of DNA ladder formation and cell
morphology such as chromatin condensation and nuclear fragmentation
consistently revealed that lidocaine enhanced apoptosis induced by
hyperthermia in U937 cells.

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 2.
Enhancement of DNA ladder formation by
lidocaine in U937 cells. U937 cells were treated with hyperthermia
(44 °C, 10 min) in the presence or absence of lidocaine, and
DNA was extracted from control and treated cells after a 6-h incubation
at 37 °C. The formation of DNA ladder was examined in 1.2% agarose
gel electrophoresis.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 3.
Apoptotic features induced by the combination
with hyperthermia and lidocaine in U937 cells. After treatment
with hyperthermia (44 °C, 10 min) in the presence or absence of 1 mM lidocaine, cells were incubated for 6 h at
37 °C. They were collected for Giemsa staining and examined under a
microscope at a magnification of ×400. A, 37 °C;
B, 37 °C with 1 mM lidocaine; C,
44 °C; D, 44 °C with 1 mM lidocaine.
E, percentage of cells showing apoptotic features.
Bars represent mean ± S.D. (n = 3).
|
|
Kinetics of Early Apoptosis and Secondary Necrosis--
Flow
cytometry using annexin V/FITC and PI double staining revealed that
after the combined treatment of hyperthermia and lidocaine, the cells
with externalized phosphatidylserine significantly increased depending
on the incubation time. This phosphatidylserine externalization is an
early sign of apoptosis (Fig. 4). At
6 h, the percentage of early apoptosis, i.e. annexin
V(+)/PI(
) cells, induced by the combined treatment (52.0 ± 5.0, mean ± S.D., n = 3) was significantly higher than
that in the cells treated with hyperthermia alone (16.3 ± 6.3).
In contrast, the percentage of secondary necrosis, i.e.
annexin V(+)/PI(+), was small and was less than 20% even in the cells
treated with hyperthermia and lidocaine.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Flow cytometry of early apoptosis and
secondary necrosis combined with lidocaine in U937 cells. U937
cells were treated with hyperthermia (44 °C, 10 min) in the presence
of 1 mM lidocaine and incubated for 1, 3, and 6 h at
37 °C. The percentages of early apoptotic (A) and
secondary necrotic (B) cells were determined by flow
cytometry with annexin V/FITC and PI double staining. Data are
presented as mean ± S.D. (n = 3).
|
|
Analysis of the Ca2+-dependent
Pathway--
Because U937 cells have been reported to possess a
Ca2+-dependent apoptosis pathway (16-18), we
carried out digital imaging of Fura-2 fluorescence to examine the
change in [Ca2+]i immediately after the treatment
of hyperthermia combined with or without lidocaine. The average
[Ca2+]i was 83.8 ± 38.7 nM in
the control cells (mean ± S.D., n = 500),
77.3 ± 44.2 nM in the cells treated with lidocaine
alone, 100.5 ± 61.6 nM in the cells treated with
hyperthermia alone, and 140.4 ± 119.8 nM in the cells
treated with hyperthermia and lidocaine.
As shown in Fig. 5, E-H
(histograms of [Ca2+]i in 500 randomly selected
cells) the distribution in the non-treated control cells and in the
cells treated with lidocaine alone was relatively uniform. In contrast
when the cells were treated with hyperthermia, especially when combined
with lidocaine, the number of cells containing higher
[Ca2+]i increased markedly. Because the
[Ca2+]i in ~95% of control cells was less than
135 nM, the fraction of cells showing above 135 nM was calculated and evaluated for statistical
significance. No significant difference in the fraction of cells
containing above 135 nM between the control (3.3 ± 5.9%, mean ± S.D., n = 5) and the cells treated
with lidocaine (6.0 ± 7.1%) was observed. When the cells were
treated with hyperthermia the fraction of cells showing higher
[Ca2+]i (16.7 ± 7.1%) increased
significantly compared with the control (p < 0.05).
Furthermore, when the cells were treated with hyperthermia combined
with lidocaine the fraction of cells (31.0 ± 20.3%) increased
significantly compared with the cells treated with hyperthermia
(p < 0.01). These results indicate that lidocaine
further increased the hyperthermia-induced increase in
[Ca2+]i.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of hyperthermia combined with
lidocaine on [Ca2+]i. Immediately after
treatment with hyperthermia (44 °C, 10 min) in the presence or
absence of lidocaine (1 mM) cells were stained with
Fura-2/AM as described under "Experimental Procedures," and
[Ca2+]i were then measured. A-D,
digital images of Fura-2 fluorescence. E-H,
histograms of [Ca2+]i.
|
|
To explore reasons why the [Ca2+]i
increased when the cells were treated with hyperthermia combined with
the presence or absence of lidocaine, the expression of
IP3R proteins (types 1 and 3), which is known to be related
to intracellular Ca2+ homeostasis (26, 27), was examined.
Western blotting of whole cell extracts with IP3R-specific
antibody showed that proteins of IP3R1 were slightly
expressed in the U937 cells and therefore the expression was
increased with hyperthermia alone immediately after the treatment (Fig.
6). However, no further increase was observed in the cells treated with hyperthermia and lidocaine. In
contrast, no expression of IP3R3 was detected in the
control cells and in the cells treated with hyperthermia combined with the presence or absence of lidocaine. The increase in
[Ca2+]i induced by hyperthermia caused by the
elevation of IP3R1 expression was revealed. This finding
suggests that the intracellular release of Ca2+ from store
sites induced by hyperthermia is a reason for the initial increase
in [Ca2+]i.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
Western blot analyses of IP3R
protein expression immediately after hyperthermia combined with
lidocaine. Cells were collected immediately after hyperthermia
combined with lidocaine. After being lysed in a radioimmune
precipitation buffer for 15 min, equal amounts of protein (50 µg)
were electrophoresed, transferred to Immobilon, blocked with skim milk
(5%) for 2 h, and incubated with goat polyclonal IgG (1:500) for
3 h at room temperature. IP3R1 protein was detected
after incubation with horseradish peroxidase-linked anti-goat IgG
(1:1000) for 1 h followed by chromogenic visualization with BLAST
4CN plus.
|
|
Analysis of the Mitochondrial Caspase-dependent
Pathway--
To examine whether the mitochondrial
caspase-dependent pathway for apoptosis is related to the
enhancement of hyperthermia-induced apoptosis by lidocaine or not, we
measured the MMP change, the intracellular superoxide anion radical
level, and the intracellular caspase-3 activities. When the cells were
treated with hyperthermia in the presence of lidocaine and incubated at
37 °C for 6 h, cells with low MMP (Fig.
7), a high level of superoxide anion
radicals, and high activities of caspase-3 (Fig.
8) increased significantly. The
percentage of cells with high superoxide anion radical levels was
1.8 ± 0.4% in the control cells (mean ± S.D.,
n = 3), 3.9 ± 2.5% in the cells treated with
lidocaine alone, 4.4 ± 0.5% in the cells treated with
hyperthermia, and 57.4 ± 15.4% in the cells treated with
hyperthermia and lidocaine. These results confirmed our
hypothesis that the activation of mitochondria-caspase pathway is involved in the enhancement of hyperthermia-induced apoptosis by lidocaine.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Loss of MMP after hyperthermia combined with
lidocaine. After treatment with hyperthermia (44 °C, 10 min) in
the presence or absence of 1 mM lidocaine cells were
incubated for 6 h at 37 °C. They were stained with 40 nM DiOC6(3) as described under "Experimental
Procedures," and then MMP was measured by flow cytometry.
A, 37 °C; B, 37 °C with 1 mM
lidocaine; C, 44 °C; D, 44 °C with 1 mM lidocaine. E, percentage of cells with low
MMP. Bars in figures represent mean ± S.D.
(n = 3).
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 8.
Increase of caspase-3 activity after
hyperthermia combined with lidocaine. After treatment with
hyperthermia (44 °C, 10 min) in the presence or absence of 1 mM lidocaine, cells were incubated for 6 h at
37 °C. They were stained with PhiPhiLux-G1D2 as described under
"Experimental Procedures," and then caspase activity was measured
by flow cytometry. A, 37 °C; B, 37 °C with
1 mM lidocaine; C, 44 °C; D,
44 °C with 1 mM lidocaine. E, percentage of
cells showing high caspase-3 activities. Bars in figures
represent mean ± S.D. (n = 3)
|
|
Because apoptosis has been known to depend strongly on the
intracellular concentration of ATP (28, 29) and our result shows that
mitochondria are related to the enhancement of hyperthermia-induced apoptosis by lidocaine, the ATP concentration in cells treated with
various concentrations of lidocaine with or without hyperthermia was
measured 3 h after treatment (Fig.
9). An increasing concentration of
lidocaine induced a gradual decrease in ATP concentration at 37 °C.
However, hyperthermia reduced ATP concentration to a level similar to
that attained when lidocaine alone was used and significantly decreased
it furthermore to 11.2 ± 3.4% (mean ± S.D.,
n = 4) from 100% of the control when 5 mM
lidocaine was added.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 9.
Intracellular ATP concentration after
hyperthermia combined with lidocaine. U937 cells were treated with
hyperthermia (44 °C, 10 min) in the presence or absence of LAs at
different concentrations. After incubation for 3 h at 37 °C,
intracellular ATP concentration (103 cells) was measured
using a CheckLite plus 250 kit as described under "Experimental
Procedures." Data are presented as mean ± S.D.
(n = 4).
|
|
Effects of BAPTA-AM on DNA Fragmentation--
To examine the role
of [Ca2+]i on the enhancement of
hyperthermia-induced apoptosis by lidocaine, a cytosolic free Ca2+ chelator, BAPTA-AM, was utilized. When cells were
treated and incubated for 6 h in the presence of BAPTA-AM at a
concentration of 50 µM, the inhibition rates (IRs) by
BAPTA-AM on DNA fragmentation, on the fraction of cells expressing
superoxide formation, on cells with low MMP, and on cells with
activated caspase-3 were obtained. IR was calculated as: IR (%) = [(FHL
FHLB)/FHL] × 100, where
FHL is percent in the cells treated with hyperthermia and
lidocaine and FHLB is percent in the cells treated with
hyperthermia and lidocaine in the presence of BAPTA-AM. BAPTA-AM
significantly reduced these end points of apoptosis induced by
hyperthermia and lidocaine. The IR on DNA fragmentation, on the
fraction of cells expressing superoxide formation, on cells with low
mitochondria membrane potential, and on cells with activated caspase-3
are 60.9 ± 5.1% (mean ± S.D., n = 5),
50.9 ± 5.2% (mean ± S.D., n = 5),
42.9 ± 8.6% (mean ± S.D., n = 4), and
38.0 ± 17.6% (mean ± S.D., n = 3),
respectively (Fig. 10).

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 10.
Effects of BAPTA-AM on DNA
fragmentation. When cells were treated and incubated for 6 h
in the presence of BAPTA-AM at a concentration of 50 µM,
the inhibition rate by BAPTA-AM on DNA fragmentation, that of the
fraction of cells expressing superoxide formation, that of cells with
low MMP, and that of cells with activated caspase-3 was
obtained. The IR was calculated as follows: IR (%) = [(FHL FHLB)/FHL] × 100, where
FHL is percent in the cells treated with hyperthermia and
lidocaine and FHLB is percent in the cells treated with
hyperthermia and lidocaine in the presence of BAPTA-AM. Data are
presented as mean ± S.D. (n = 3-5).
|
|
In contrast, the reduced ATP concentration in cells treated with
hyperthermia and lidocaine further decreased by 75.7 ± 5.2% in
the presence of BAPTA-AM.
 |
DISCUSSION |
LAs have been reported to enhance cell killing induced by
hyperthermia either in vitro or in vivo (10, 12,
30). Previous studies have demonstrated that LAs interact extensively
with the cell membrane. For example, LAs induce disorders among the
lipid part of the cell membrane, fluidizing and expanding it by
nonspecific binding (13, 31). LAs raise the intracellular calcium ion level (32, 33), inhibit Ca2+, Mg2+-ATPase
activity (34), and reduce the mitochondrial oxidative energy metabolism
(35). However, the mechanism by which LAs potentiate hyperthermic
damage to cells is not clearly understood, and little is known about
the modification of hyperthermia-induced apoptosis by LAs. The present
results reveal that the mechanism of enhancement of
hyperthermia-induced apoptosis by lidocaine involves increasing the
initial release of Ca2+ from intracellular store sites
caused by hyperthermia and a subsequent increase in
[Ca2+]i, and the results also reveal that
activation of a mitochondria-caspase pathway is accompanied by a loss
of mitochondrial membrane potential, superoxide production, and
activation of caspase-3 (See Fig.
11).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 11.
Mechanism of enhancement of
hyperthermia-induced apoptosis by LAs. Fine arrows indicate
the pathway induced by hyperthermia alone. Bold arrows
indicate the pathway induced when hyperthermia was combined with
lidocaine.
|
|
The cytotoxic effects of hyperthermia as measured by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) method (13) were enhanced by subtoxic levels
of anesthetics, and the potency of these effects was related to their
respective lipophilicity (13, 25). Fluidization of the hydrophobic core of the membrane may contribute to anesthetic potentiation of
heat-induced cell death (13). In addition, bupivacaine (because of its
high lipophilicity) penetrated the cell membrane, reached the
mitochondria to induce deep ultrastructural modifications, and lowered
the MMP (35). In this study, the order of the concentration of LAs for
the maximum DNA fragmentation at 44 °C was in the reverse order of
their lipophilicity. LAs with high lipophilicity may cause much more
sensitization of cells to hyperthermia by interacting with and
destabilizing membranes so that fluidity is increased, because higher
lipophilicity makes it easy for LAs to integrate in the cell membrane.
Therefore, LAs with higher lipophilicity appear to cause greater
enhancement of hyperthermia-induced apoptosis.
When the cells were treated with hyperthermia and lidocaine in the
range of toxic concentrations a decrease in DNA fragmentation, early
apoptosis, and an increase in secondary necrosis were observed. It is
well known that a fall in ATP eventually causes various cellular
abnormalities, which may lead to cell death (28), and changes the type
of cell death from apoptosis to necrosis (29). Therefore, it is
possible that the decrease in intracellular ATP concentration is
related to this change of cell death from apoptosis to necrosis. In
this study the promotion of a decrease in the intracellular ATP
concentration and a subsequent drop in DNA fragmentation by
hyperthermia combined with lidocaine was observed.
The increase in intracellular Ca2+ concentration after
treatment of hyperthermia combined with lidocaine and the suppression of DNA fragmentation by a Ca2+ chelator (BAPTA-AM) suggest
that a Ca2+-dependent pathway is involved in
the enhancement of hyperthermia-induced apoptosis by lidocaine. The
small increase in [Ca2+]i after hyperthermia
appears to be caused by an initial release of Ca2+ (derived
from the intracellular storage sites) because expression of
IP3R1 was up-regulated immediately after hyperthermia.
Subsequently, the decrease in intracellular ATP concentration
facilitated by lidocaine led to a rapid decline in the
Ca2+-ATPase activity, and the accumulation of intracellular
Ca2+ due to an abatement of Ca2+ exclusion (33)
appears to cause the activation of
Ca2+-dependent endonucleases and proteases in apoptosis.
Involvement of the mitochondrial caspase-dependent
apoptosis pathway was also indicated because of the lowering of
the mitochondrial membrane potential, the increase in
O
production, and the activation of
intracellular caspase-3. There have been some reports that LAs alone
with high lipophilicity could reach mitochondria (36) and that LAs not
only induce uncoupling of mitochondria by an electrophoretic mechanism
but also inhibit adenine nucleotide transport in mitochondria (37).
Another study has reported that LAs at high concentrations induced
apoptosis and appear to be related to activation of the
mitochondria-caspase pathway, but they may not interact directly with
mitochondria in HL-60 cells to induce apoptosis (38). Because LAs at
toxic concentrations induced apoptosis dependent on the
mitochondria-caspase pathway whether they interacted with the
mitochondria directly or indirectly, it is possible that hyperthermia
further enhanced activation of the mitochondrial
caspase-dependent pathway in apoptosis induced by LAs even
at lower nontoxic concentrations.
To understand better the significance of the increase in
[Ca2+]i in cells treated with hyperthermia and
lidocaine, various parameters of the mitochondrial
caspase-dependent apoptotic pathway were examined in
the presence of a cytosolic free Ca2+ chelator, BAPTA-AM,
at a concentration of 50 µM (because 50 µM BAPTA-AM has shown significant inhibition of hyperthermia-induced DNA
fragmentation in U937 cells) (21). When cells were treated and
incubated for 6 h in the presence of BAPTA-AM, enhancement of DNA
fragmentation by lidocaine combined with hyperthermia was decreased by
60.9 ± 5.1%. In addition decreases in MMP, superoxide formation,
and activation of intracellular caspase-3 by hyperthermia combined with
lidocaine were suppressed by approximately 40-50% (Fig. 10).
These results indicate that the rise in intracellular free
Ca2+ takes part not only in the
Ca2+-dependent pathway but also in the
mitochondrial caspase-dependent pathway. In addition
because a series of parameters on the mitochondrial caspase-dependent pathway in cells treated with
hyperthermia and lidocaine was suppressed by BAPTA-AM, direct
involvement of intracellular free Ca2+ upon the
mitochondria is suggested. These results support the view that
elevations in cytosolic Ca2+ act directly on mitochondria
to induce the rupture of the outer membrane and the release of caspase
activation proteins (reviewed in Ref. 39).
In contrast, the reduced intracellular ATP concentration (another
parameter that relates to mitochondrial function and cell death) in the
cells treated with hyperthermia and lidocaine was further decreased by
75.7 ± 5.2% in the presence of BAPTA-AM. However, when cells
were treated with BAPTA-AM alone the ATP concentration was decreased
very markedly by 93.2 ± 1.4%. For this reason, the relationship
between the rise in intracellular free Ca2+ and the
decrease in intracellular ATP concentration in the cells treated with
hyperthermia combined with lidocaine has not been resolved. Therefore,
the role of intracellular ATP in the mitochondrial caspase-dependent pathway cannot be fully established
because BAPTA-AM did not prevent the decrease of ATP concentration.
The molecular mechanism of the enhancement of apoptosis by LAs at
hyperthermic temperature has not been established. However, we obtained
evidence for the cardinal roles of the initial release of
Ca2+ from intracellular store sites caused by hyperthermia
and the subsequent increase of [Ca2+]i and for
the additional activation of the mitochondrial caspase-dependent pathway, which was partly regulated by
intracellular Ca2+ concentration in the enhancement of
apoptosis induced by the combination of hyperthermia and lidocaine. In
conclusion we present the possible effectiveness of the use of LAs in
cancer treatment in combination with hyperthermia. LAs enhance
hyperthermia-induced apoptosis at non-cytotoxic concentrations when
applied alone. It is hoped that a better understanding of the mechanism
of apoptosis induced by hyperthermia and LAs, which are well known in
pharmacology and toxicology and for which there is extensive clinical
experience, will lead to the development of better strategies for use
in cancer therapy.
 |
ACKNOWLEDGEMENTS |
We acknowledge valuable discussions
with Dr. Peter Riesz, NCI, National Institutes of Health,
Bethesda, Maryland and Dr. Loreto B. Feril, Department of
Radiological Sciences, Faculty of Medicine, Toyama Medical and
Pharmaceutical University.
 |
FOOTNOTES |
*
This study was supported in part by a Grant-in-aid for
Scientific Research on Priority Areas (C) (12217049) from the
Ministry of Education, Culture, Sports, Science, and Technology, Japan.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed. Tel.: 81-76-434-7265;
Fax: 81-76-434-5190; E-mail: kondot@ms.toyama-mpu.ac.jp.
Published, JBC Papers in Press, February 22, 2002, DOI 10.1074/jbc.M108084200
 |
ABBREVIATIONS |
The abbreviations used are:
LA, local
anesthetic;
BAPTA-AM, bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic
acid-acetoxymethyl;
PBS, phosphate-buffered saline;
PI, propidium
iodide;
FITC, fluorescein isothiocyanate;
IR, inhibition rate;
HR, HEPES-buffer Ringer solution;
MMP, mitochondrial membrane potential;
IP3R, inositol-1,4,5-trisphosphate receptor;
DiOC6(3), 3,3-deoxycarbocyanene iodide.
 |
REFERENCES |
| 1.
|
Overgaard, J.
(1989)
Int. J. Radiat. Oncol. Biol. Phys.
16,
535-549[Medline]
[Order article via Infotrieve]
|
| 2.
|
Seegenschmiedt, M. H.,
Feldmann, H. J.,
Wust, P.,
and Molls, M.
(1995)
Strahlenther. Onkol.
171,
560-572[Medline]
[Order article via Infotrieve]
|
| 3.
|
Sneed, P. K.,
Stauffer, P. R.,
McDermott, M. W.,
Diederich, C. J.,
Lamborn, K. R.,
Prados, M. D.,
Chang, S.,
Weaver, K. A.,
Spry, L.,
Malec, M. K.,
Lamb, S. A.,
Voss, B.,
Davis, R. L.,
Wara, W. M.,
Larson, D. A.,
et al..
(1998)
Int. J. Radiat. Oncol. Biol. Phys.
40,
287-295[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Overgaard, J.,
Gonzalez Gonzalez, D.,
Hulshof, M. C. C. H.,
Arcangeli, G.,
Dahl, O.,
Mella, O.,
and Bentzen, S.
(1996)
Int. J. Hyperth.
12,
3-20[Medline]
[Order article via Infotrieve]
|
| 5.
|
Vernon, C. C.,
Hand, J. W.,
Field, S. B.,
Machin, D.,
Whaley, J. B.,
van der Zee, J.,
van Putten, W. L.,
van Rhoon, G. C.,
van Dijk, J. D.,
Gonzalez Gonzalez, D.,
Liu, F. F.,
Goodman, P.,
and Sherar, M.
(1996)
Int. J. Radiat. Oncol. Biol. Phys.
35,
731-744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
van der Zee, J.,
Gonzalez Gonzalez, D.,
van Rhoon, G. C.,
van Dijk, J. D.,
van Putten, W. L.,
and Hart, A. A.
(2000)
Lancet
355,
1119-1125[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Wessalowski, R.,
Kruck, H.,
Pape, H.,
Kahn, T.,
Willers, R.,
and Gobel, U.
(1998)
Cancer
82,
793-800[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Yau, T. M.
(1979)
Radiat. Res.
80,
523-541[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Mizuno, S.,
and Ishida, A.
(1982)
Cancer Res.
42,
4726-4729[Abstract/Free Full Text]
|
| 10.
|
Yatvin, M. B.,
Clifton, K. H.,
and Dennis, W. H.
(1979)
Science
205,
195-196[Abstract/Free Full Text]
|
| 11.
|
Clark, A. W.,
Robins, H. I.,
Vorpahl, J. W.,
and Yatvin, M. B.
(1983)
Cancer Res.
43,
1716-1723[Abstract/Free Full Text]
|
| 12.
|
Robins, H. I.,
Dennis, W. H,
Slattery, J.,
Lange, T. A.,
and Yatvin, M. B.
(1983)
Cancer Res.
43,
3187-3191[Abstract/Free Full Text]
|
| 13.
|
Kingston, C. A.,
Ladha, S.,
Manning, R.,
and Bowler, K.
(1993)
Anticancer Res.
13,
2235-2240
|
| 14.
|
Sellins, K. S.,
and Cohen, J. J.
(1987)
J. Immunol.
139,
3199-3206[Abstract]
|
| 15.
|
Hopcia, K. L.,
McCarey, Y. L.,
Sylvester, F. C.,
and Held, K. D.
(1996)
Radiat. Res.
145,
315-323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Kimura, C.,
Zhao, Q. L.,
Kondo, T.,
Amatsu, M.,
and Fujiwara, Y.
(1998)
Exp. Cell Res.
239,
411-422[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Li, M.,
Kondo, T.,
Zhao, Q. L., Li, F. J.,
Tanabe, K.,
Arai, Y.,
Zhou, Z. C.,
and Kasuya, M.
(2000)
J. Biol. Chem.
275,
39702-39709[Abstract/Free Full Text]
|
| 18.
|
van Heerde, W. L.,
de Groot, P. G.,
and Reutelingsperger, C. P. M.
(1995)
Thromb. Haemostasis
73,
172-179[Medline]
[Order article via Infotrieve]
|
| 19.
|
Habara, H.,
and Kanno, T.
(1991)
Cell Calcium
12,
533-542[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Kondo, T.,
Kano, E.,
Habara, Y.,
and Kanno, T.
(1993)
Cell Calcium
14,
621-629[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Kameda, K.,
Kondo, T.,
Tanabe, K.,
Zhao, Q. L.,
and Seto, H.
(2001)
Int. J. Radiat. Oncol. Biol. Phys.
49,
1369-1379[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Grynkiewicz, G.,
Poenie, M.,
and Tsien, R. Y.
(1985)
J. Biol. Chem.
260,
3440-3450[Abstract/Free Full Text]
|
| 23.
|
Gorman, A.,
McGowan, A.,
and Cotter, T. G.
(1997)
FEBS Lett.
404,
27-33[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Zapta, J. M.,
Takahashi, R.,
Salvesen, G. S.,
and Reed, J. C.
(1998)
J. Biol. Chem.
273,
6916-6920[Abstract/Free Full Text]
|
| 25.
|
Scurr, C.,
Feldman, S.,
and Sone, N.
(1990)
Scientific Foundation of Anesthesia
, pp. 636-641, Year Book Medical Publishers, Inc., Chicago
|
| 26.
|
Khan, A. A.,
Soloski, M. J.,
Sharp, A. H.,
Schilling, G.,
Sabatini, D. M., Li, S. H.,
Ross, C. A.,
and Snyder, S. H.
(1996)
Science
273,
503-507[Abstract]
|
| 27.
|
Jayaraman, T.,
and Marks, A. R.
(1997)
Mol. Cell. Biol.
17,
3005-3012[Abstract]
|
| 28.
|
Eguchi, Y.,
Shimizu, S.,
and Tsujimoto, Y.
(1997)
Cancer Res.
57,
1835-1840[Abstract/Free Full Text]
|
| 29.
|
Eguchi, Y.,
Srinivasan, A.,
Tomaselli, K. J.,
Shimizu, S.,
and Tsujimoto, Y.
(1999)
Cancer Res.
59,
2174-2181[Abstract/Free Full Text]
|
| 30.
|
Robins, H. I.,
Dennis, W. H.,
Martin, P. A.,
Sondel, P. M.,
Yatvin, M. B.,
and Steeves, R. A.
(1984)
Cancer
54,
2831-2835[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Ueda, I.,
Tashiro, C.,
and Arakawa, K.
(1977)
Anesthesiology
46,
327-332[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Coss, R. A.,
Felgar, R. E.,
Stokes, D. G.,
and Smith, N. N.
(1989)
Int. J. Hyperth.
5,
383-387[Medline]
[Order article via Infotrieve]
|
| 33.
|
Butterworth, J. F.,
and Strichartz, G. R.
(1990)
Anesthesiology
72,
711-734[Medline]
[Order article via Infotrieve]
|
| 34.
|
Senisterra, G. A.,
and Lepock, J. R.
(2000)
Int. J. Hyperth.
16,
1-17[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Bruno, T.,
Gentile, F. P., Di,
Padova, M.,
Antonucci, E.,
Rubiu, O.,
Dolo, V.,
Pavan, A.,
and Floridi, A.
(1998)
Oncol. Res.
10,
143-150[Medline]
[Order article via Infotrieve]
|
| 36.
|
Grouselle, M.,
Tueux, O.,
Dabadie, P.,
Georgescaud, D.,
and Mazat, J. P.
(1990)
Biochem. J.
271,
269-272[Medline]
[Order article via Infotrieve]
|
| 37.
|
Karniel, M.,
and Beitner, R.
(2000)
Mol. Genet. Metab.
69,
40-45[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Arita, K.,
Utsumi, T.,
Kato, A.,
Kanno, T.,
Kobuchi, H.,
Inoue, B.,
Akiyama, J.,
and Utsumi, K.
(2000)
Biochem. Pharmacol.
60,
905-915[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Green, R. G.,
and Reed, J. C.
(1998)
Science.
281,
1309-1312[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. Lirk, I. Haller, H. P. Colvin, L. Lang, B. Tomaselli, L. Klimaschewski, and P. Gerner
In Vitro, Inhibition of Mitogen-Activated Protein Kinase Pathways Protects Against Bupivacaine- and Ropivacaine-Induced Neurotoxicity
Anesth. Analg.,
May 1, 2008;
106(5):
1456 - 1464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Onizuka, T. Kasaba, R. Tamura, and M. Takasaki
Lidocaine Increases Intracellular Sodium Concentration Through a Na+-H+ Exchanger in an Identified Lymnaea Neuron
Anesth. Analg.,
May 1, 2008;
106(5):
1465 - 1472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sakaguchi, Y. Kuroda, and M. Hirose
The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor.
Anesth. Analg.,
April 1, 2006;
102(4):
1103 - 1107.
[Abstract]
[Full Text]
[PDF]
|
 |
|